Call topic identification for 2019 call

Slides:

Advertisements

Similar presentations

TVET working group contributions. What are the possible options for obtaining decent living and working conditions without joining the informal economy?

Advertisements

Strategic Information for Anti-RetroViral Treatment Programmes Workshop WHO and UNAIDS Geneva June 30- July Ties Boerma HIV Department Surveillance,

Contribution of Economics to Operational Research for Evaluation of Scaling Up Access to HIV Care & Treatment in Developing Countries Presentation by Pr.

EU RTD + FP Cancer Treatment: A priority for patients in Europe 7 th European Health Forum Bad Gastein 7 October, 2004 Cornelius Schmaltz MD European.

Successor to the Strategy for Science, Technology and Innovation HRB and Department of Health Consultation Workshop 11 March 2015 Dermot Curran Assistant.

Knowledge Translation Curriculum Module 3: Priority Setting Lesson 2 - Interpretive Priority Setting Processes.

TRAINING FOR ANTIMICROBIAL STEWARDSHIP PROGRAMMES IN HOSPITALS JUNE 2014.

Antimicrobial resistance “One health fits all”

U.S. Department of Agriculture Proposed Activities to Address Antibiotic Resistance Secretary’s Advisory Council on Animal Health April 29, 2015 L.M. Granger,

TBS November 4, |1 | AMR and appropriate use of antimicrobials Nicola Magrini and Jane Robertson Policy, Access and Use Team, EMP TBS 4 November.

Title of Presentation 1 EU-ASEAN S&T cooperation to jointly tackle societal challenges Opportunities for future EU-ASEAN collaborations.

Emerging infections and Health Protection In Scotland Looking to the future Kirsty Roy and Martin Donaghy Health Protection Scotland Scottish Government.

Risk Management and NSQHS Standards, Standard 3 – Preventing and Controlling Healthcare Associated Infections Sue Greig Senior Project Officer National.

Data Requirements for Field Release and Monitoring Jon Knight Imperial College London

Hans Wolf-Watz, professor, UCMR, MIMS, Department of Microbiology, Umeå University, Sweden, Antibiotic resistance a new.

European Health Forum Gastein, Bad Hofgastein, Austria, September 2002 Towards the Sixth Framework Programme Parallel Forum V 26 September 2002 Public.

Health Promoting Health Service: Development day.

Operational Research in the 21 st Century. International Union Against Tuberculosis and Lung Disease (The Union) World’s oldest humanitarian organization.

European Health Forum Gastein, Bad Hofgastein, Austria, September 2002 The Sixth Framework Programme and Policy Support Research – “Priority 8” Parallel.

PAHO Pan American Health Organization Pan American Sanitary Bureau Regional Office for the Americas for the World Health Organization.

Unit 10. Monitoring and evaluation

The Antimicrobial Resistance Issue A briefing for the Secretaries Advisory Committee on Animal Health June 19, 2014.

Ecdc.europa.eu Tommi Asikainen, Tubingen, 22 October 2008 European Centre for Disease Prevention and Control FUTURE DISEASE CHALLENGES IN EUROPE – where.

African Business Leaders on Health: GBC Conference on TB, HIV-TB Co-infection & Global Fund Partnership Johannesburg, October 11, 2010 The state of Global.

Strategic Priorities of the NWE INTERREG IVB Programme Harry Knottley, UK representative in the International Working Party Lille, 5th March 2007.

EU Funding opportunities : Rights, Equality and Citizenship Programme Justice Programme Jose Ortega European Commission DG Justice.

Clinical trials in Framework programme 7 (FP7) EU Judita Kinkorová 2. Národní konference o doporučených postupech, Olomouc 13. listopadu 2010.

Epilepsy and WHO | 17 Oct |1 | WHO's six-point agenda The overarching health needs 1.Promoting development 2.Fostering health security The strategic.

A Strategic Research Agenda for Europe in the field of illicit drugs Priorities for socio-economic and humanities research HDG Brussels - December 10,

The WHO HIV Drug Resistance Strategy Presented by Dr. Don Sutherland Prepared by: Dr. Don Sutherland Dr Silvia Bertagnolio Dr Diane Bennett HIV Drug Resistance.

XVII INTERNATIONAL AIDS CONFERENCE PANCAP Satellite Meeting Hon Douglas Slater, Minister of Health, St. Vincent and the Grenadines.

The ERA-NET TRANSCAN-2, in continuity with the preceding ERA-NET TRANSCAN, aims at linking translational cancer research funding programmes in 15 Member.

Consultant Advance Research Team. Outline UNDERSTANDING M&E DATA NEEDS PEOPLE, PARTNERSHIP AND PLANNING 1.Organizational structures with HIV M&E functions.

EC actions against the rising threats from Antimicrobial Resistance

Perspectives on containing antimicrobial resistance – ways to go … Karl Ekdahl, Strategic Advisor on behalf of Zsuzsanna Jakab, Director European Centre.

GENOMICS TO COMBAT RESISTANCE AGAINST ANTIBIOTICS IN COMMUNITY-ACQUIRED LRTI IN EUROPE (GRACE) H. Goossens (Coordinator), K. Loens (Manager), M. Ieven.

Ministerial Declaration and Concluding Remarks MD PhD Karin Tegmark Wisell Chair AMR expert group, NDPHS.

Laura Marin Project Manager of JPIAMR Central Secretariat Swedish Research Council April 2016 From national plans to joint calls and capacity.

Using AMR surveillance for developing policy AMR meeting Washington 13 April 2016.

European network for Health Technology Assessment | JA | EUnetHTA European network for Health Technology Assessment THL Info.

The role of PHE’s AMRHAI Reference Unit Professor Neil Woodford Antimicrobial Resistance & Healthcare Associated Infections (AMRHAI) Reference Unit © Crown.

2007 Pan American Health Organization 2004 Pan American Health Organization Malaria in the Americas: Progress, Challenges, Strategies and Main Activities.

EU Ministerial AMR One Health Conference 10Feb16 Outcome Summary National Interdepartmental Consultative AMR Committee Meeting 13Apr16.

TB AND HIV: “THE STRATEGIC VISION FOR THE COUNTRY” Dr Lindiwe Mvusi 18 May 2012 MMPA Congress 2012.

WHO’s prioritised research agenda for the prevention and control of NCDs prioritises

Global and national approaches to reducing the harmful use of alcohol

Work Programme The social challenge “Health, Demographic Change and Wellbeing” Maia Okujava NCP for Health, Demographic Change and weii-being,

Surveillance. Public Health Approach Surveillance What is the Problem ? Problem Risk Factor Identification : What Is the Cause ? Intervention Evaluation.

Declaration of the 11th ministerial-level PAC meeting in Berlin 2015 From strategies to action – how to tackle the challenges of Antimicrobial Resistance.

Monitoring the implementation of the TB Action Plan for the WHO European Region, 2016–2020 EU/EEA situation in 2016 ECDC Tuberculosis Programme European.

Including AMR Scientists in LMICs in JPIAMR Calls for multidisciplinary studies, including One Health approaches Maria Teresa Bejarano. MD, PhD Senior.

Antimicrobial Resistance: Plans for Korea and Beyond

The Commission Strategy on TB vaccine research

Interpretation of local, national and European level results

Antiretroviral therapy coverage in sub-Saharan Africa,

Antibiotic Resistance: Strategic Solutions

Global Action Plan on HIVDR 2018 Progress Report

Impact of JPIAMR funded projects: Strategy development

The International Consortium for Personalised Medicine

ENI CBC Joint Operational Programme Black Sea Basin

JPIAMR Joint Research Calls – Update and Future Calls

Essential Drugs and Medicines Policy

Work Programme 2012 COOPERATION Theme 6 Environment (including climate change) Challenge 6.4 Protecting citizens from environmental hazards European.

Essential Drugs and Medicines Policy

National Center for Emerging and Zoonotic Infectious Diseases

The STOP TB Strategy – 2009 VISION: A TB-free world

SRIA Roadmap Jonathan Pearce

Management Board Meeting, 2-3 April 2019, Basel

SRIA Roadmap Jonathan Pearce OBJECTIVE OF THE EXCERCISE.

Comprehensive M&E Systems

Presentation transcript:

Call topic identification for 2019 call Laura Plant JPIAMR Secretariat 26th February 2018

JPIAMR Calls to date… 2014 Therapeutics: InnovaResistance: Innovative approaches to address antibacterial resistance 2015 Therapeutics: Antimicrobial Resistance through the JPIAMR 2016 Transmission: Transmission Dynamics 2017 Intervention : Comparison of prevention, control and intervention strategies for AMR infections through multidisciplinary studies, including One Health approaches 2018 Therapeutics: Innovations against antibiotic-resistant bacteria: new targets, compounds and tools. Fundamental, translational research, with the exception of clinical trials

2019 Call topic process Survey open from Dec 2017 to Jan 2018. Twelve ares surveyed, asking the following questions: Topic has a high impact on reducing the burden of AMR? Topic has a high impact on translation of research into clinical practice, commercialisation of output, and policy uptake? Topic enables larger scale projects that use data and infrastructure not available within a single country (avoids fragmentation and duplication)? Topic will create new networks including researchers from countries not represented adequately up to now? Topic enhances capacity building in countries not represented adequately up to now? Topic strengthens the European or other regional research areas? Questions 1 and 2 surveyed the importance of the topic to the issue of AMR, while questions 3-6 addressed the benefit of running the call as a joint transnational call. Both aspects were weighted equally in the analysis of the results of the survey.

Survey Topic 2019: DIAGNOSTICS Identification of appropriate diagnostic markers or development and validation of new better diagnostic tools and methods for discrimination between viral and bacterial infections, detecting and identifying antibiotic resistant bacteria, and/or monitoring the clinically relevant load of resistant pathogens. Tests should be rapid, reliable, and affordable and developed for specific pathologies to be implemented bedside/point of care for antimicrobial susceptibility testing in order to promote the use of narrow spectrum antibiotics.

DIAGNOSTICS Other diagnostic calls IMI2-2017-13-03: AMR priority: The value of diagnostics to combat antimicrobial resistance by optimising antibiotic use. ZonMw Antibiotic Resistance: 1. Mechanisms of acquiring and transmitting antibacterial resistance in different environment such as patients, farms and nature; 2. Appropriate use of diagnostics; 3. Optimising antibiotic dosage and prudent use.

SURVEILLANCE (rank 2 and 3) Alternative Topics 2019 SURVEILLANCE (rank 2 and 3) To design and perform longitudinal or modelling studies of AMR/ATB use and/or to perform a pilot study on the feasibility of a global phenotypic and genotypic surveillance program Other surveillance calls JPIAMR 2018 Surveillance Network Call WHO GLASS surveillance programme (aiming standardised protocols) Fleming fund Surveillance ECDC and National Agencies

INTERVENTION, TRANSMISSION & ENVIRONMENT Alternative Topics 2019 INTERVENTION, TRANSMISSION & ENVIRONMENT (rank 4, 5 & 6) To evaluate strategies for (behavioural) interventions to limit the transmission of bacterial and genetic elements conferring antimicrobial resistance (AMR) at the societal and environmental level, in order to improve monitoring and risk assessment, or design and evaluate preventive and intervention measures for controlling resistance. Other intervention, transmission & environment calls JPIAMR 2018 sixth joint call focus is – new targets, compounds and tools Environmental Protection Agency Ireland: Assessment of the relative contribution of various sectors to the impact and persistence of antimicrobial resistance in the environment and development of sector-specific solutions to halt further spread.

DECISION Option A: Diagnostics Option B: Surveillance Identification of appropriate diagnostic markers or development and validation of new better diagnostic tools and methods for discrimination between viral and bacterial infections, detecting and identifying antibiotic resistant bacteria, and/or monitoring the clinically relevant load of resistant pathogens. Tests should be rapid, reliable, and affordable and developed for specific pathologies to be implemented bedside/point of care for antimicrobial susceptibility testing in order to promote the use of narrow spectrum antibiotics. Option B: Surveillance To design and perform longitudinal or modelling studies of AMR/ATB use and/or to perform a pilot study on the feasibility of a global phenotypic and genotypic surveillance program Option C: Combined Intervention, Transmission, Environment To evaluate strategies for (behavioural) interventions to limit the transmission of bacterial and genetic elements conferring antimicrobial resistance (AMR) at the societal and environmental level, in order to improve monitoring and risk assessment, or design and evaluate preventive and intervention measures for controlling resistance.